Amphastar posts Q3 2026 revenue of $207.6 million, GAAP profit of $37.8 million
Amphastar Pharmaceuticals reported third‑quarter 2026 results showing net sales of $207.6 million, an 8 % increase from the prior year. GAAP earnings were $37.8 million, or $0.87 per share, while adjusted non‑GAAP earnings were $49.3 million, or $1.14 per share. The company added $50 million to its share‑repurchase program and highlighted growth in BAQSIMI and Primatene MIST despite pricing pressure and remediation costs at its IMS facility.
Why it matters
The higher revenue and profit beat analyst expectations, which may support the stock’s recent rally. The expanded buyback indicates the board’s confidence in cash generation and could provide additional support to the share price. Ongoing remediation at the IMS plant is expected to raise manufacturing expenses in the next quarters, potentially affecting margins.
Key facts
- 1Net sales for the quarter were $207.6 million, up 8 % year over year. prnewswire.com
- 2GAAP net income totaled $37.8 million, or $0.87 per share. prnewswire.com
- 3Adjusted non‑GAAP net income was $49.3 million, or $1.14 per share. prnewswire.com
- 4The board approved an additional $50 million for the share‑repurchase program on November 4, 2026. fool.com
- 5Gross margin fell to 48.0 % from 51.4 % a year earlier due to lower pricing on high‑margin products and higher IMS manufacturing costs. fool.com
- 6IMS remediation expenses were $2 million to $3 million for the quarter, with expectations of higher costs over the next two to three quarters. fool.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.